Kasper Bernd, Achee Annie, Schuster Kathrin, Wilson Roger, van Oortmerssen Gerard, Gladdy Rebecca A, Hemming Matthew L, Huang Paul, Ingham Matthew, Jones Robin L, Pollack Seth M, Reinke Denise, Sanfilippo Roberta, Schuetze Scott M, Somaiah Neeta, Van Tine Brian A, Wilky Breelyn, Okuno Scott, Trent Jonathan
Mannheim University Medical Center, University of Heidelberg, 68167 Mannheim, Germany.
National LeioMyoSarcoma Foundation (NLMSF), Denver, CO 80222, USA.
Cancers (Basel). 2021 Feb 20;13(4):886. doi: 10.3390/cancers13040886.
As leiomyosarcoma patients are challenged by the development of metastatic disease, effective systemic therapies are the cornerstone of outcome. However, the overall activity of the currently available conventional systemic treatments and the prognosis of patients with advanced or metastatic disease are still poor, making the treatment of this patient group challenging. Therefore, in a joint effort together with patient networks and organizations, namely Sarcoma Patients EuroNet (SPAEN), the international network of sarcoma patients organizations, and the National LeioMyoSarcoma Foundation (NLMSF) in the United States, we aim to summarize state-of-the-art treatments for leiomyosarcoma patients in order to identify knowledge gaps and current unmet needs, thereby guiding the community to design innovative clinical trials and basic research and close these research gaps. This position paper arose from a leiomyosarcoma research meeting in October 2020 hosted by the NLMSF and SPAEN.
由于平滑肌肉瘤患者面临转移性疾病发展的挑战,有效的全身治疗是治疗结果的基石。然而,目前可用的传统全身治疗的总体疗效以及晚期或转移性疾病患者的预后仍然很差,这使得该患者群体的治疗具有挑战性。因此,我们与患者网络和组织共同努力,即肉瘤患者欧洲网络(SPAEN),这是一个国际肉瘤患者组织网络,以及美国国家平滑肌肉瘤基金会(NLMSF),旨在总结平滑肌肉瘤患者的最新治疗方法,以识别知识差距和当前未满足的需求,从而指导该领域设计创新的临床试验和基础研究,并填补这些研究空白。本立场文件源于2020年10月由NLMSF和SPAEN主办的一次平滑肌肉瘤研究会议。